Hospital Clinic Barcelona-ko ikertzaileekin lankidetzan egindako argitalpenak (21)

2024

  1. Tubulo-interstitial inflammation increases the risk of graft loss after the recurrence of IgA nephropathy

    Clinical Kidney Journal, Vol. 17, Núm. 1

2023

  1. Update of the recommendations on the management of the SARS-CoV-2 coronavirus pandemic (COVID-19) in kidney transplant patients

    Nefrologia, Vol. 43, Núm. 5, pp. 531-545

2020

  1. Effectiveness and safety of the conversion to MeltDose® extended-release tacrolimus from other formulations of tacrolimus in stable kidney transplant patients: A retrospective study

    Clinical Transplantation, Vol. 34, Núm. 1

  2. Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients

    Nefrologia, Vol. 40, Núm. 3, pp. 265-271

  3. Uncontrolled donation after circulatory death: A unique opportunity

    Transplantation, Vol. 104, Núm. 8, pp. 1542-1552

2019

  1. Kidney transplantation from donors after uncontrolled circulatory death: the Spanish experience

    Kidney International, Vol. 95, Núm. 2, pp. 420-428

2016

  1. Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation

    Transplant International, Vol. 29, Núm. 12, pp. 1317-1328

  2. Open-Label, Randomized Study of Transition from Tacrolimus to Sirolimus Immunosuppression in Renal Allograft Recipients

    Transplantation Direct, Vol. 2, Núm. 4

  3. Role of HHV-8 and mTOR pathway in post-transplant Kaposi sarcoma staging

    Transplant International, Vol. 29, Núm. 9, pp. 1008-1016

2013

  1. A form of apolipoprotein A-I is found specifically in relapses of focal segmental glomerulosclerosis following transplantation

    American Journal of Transplantation, Vol. 13, Núm. 2, pp. 493-500

2012

  1. Anemia control in renal transplant recipients receiving continuous erythropoietin receptor activator (C.E.R.A.) treatment: The AnemiaTrans study

    Advances in Therapy, Vol. 29, Núm. 11, pp. 979-991

  2. Avances en la inmunosupresión para el trasplante renal. Nuevas estrategias para preservar la función renal y reducir el riesgo cardiovascular

    Nefrologia, Vol. 32, Núm. 3, pp. 374-384

2011

  1. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients

    American Journal of Transplantation, Vol. 11, Núm. 9, pp. 1965-1971

  2. Erratum: Estimation of renal allograft half-life: Fact or fiction? (Nephrology Dialysis Transplantation (2011) 26 (30133018) DOI 10.1093/ndt/gfq788)

    Nephrology Dialysis Transplantation

2010

  1. Anemia control in kidney transplant patients treated with methoxy polyethylene glycol-epoetin beta (Mircera): The anemiatrans group

    Transplantation Proceedings, Vol. 42, Núm. 8, pp. 2931-2934

2009

  1. A novel risk score for mortality in renal transplant recipients beyond the first posttransplant year

    Transplantation, Vol. 88, Núm. 6, pp. 803-809

2008

  1. Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus

    Transplantation, Vol. 86, Núm. 4, pp. 620-622

2007

  1. Early Sirolimus Use With Cyclosporine Elimination Does Not Induce Progressive Proteinuria

    Transplantation Proceedings, Vol. 39, Núm. 7, pp. 2151-2152

2006

  1. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction

    Nephrology Dialysis Transplantation, Vol. 21, Núm. 11, pp. 3252-3257

2005

  1. Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma

    Transplantation Proceedings